SciSparc Submits IND Application for Tourette Syndrome Drug
SciSparc Advances Tourette Syndrome Treatment
SciSparc Ltd. (Nasdaq: SPRC), a dedicated clinical-stage pharmaceutical company, is excited to announce a significant step forward in its commitment to addressing Tourette Syndrome (TS). The company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration, marking the launch of a Phase IIb clinical trial for its proprietary drug candidate, SCI-110.
Planned Trial Locations
This promising study will take place at three well-respected centers of excellence: one at the Yale Child Study Center in the U.S., another at Hannover Medical School in Germany, and the third at the Tel Aviv Sourasky Medical Center in Israel. The collaboration among these globally recognized institutions is set to enhance the credibility and comprehensiveness of the trial, which has already received the necessary approvals from relevant ethics boards and health authorities.
Trial Objectives and Methodology
The main goal of this Phase IIb trial is to thoroughly assess the efficacy, safety, and tolerability of SCI-110 in adult patients aged 18 to 65. Participants will be randomly assigned to receive either SCI-110 or a matched placebo, with a 1:1 ratio. Efficacy will be monitored by measuring changes in tic severity using the widely recognized Yale Global Tic Severity Scale, as participants are evaluated at weeks 12 and 26 of the double-blind phase.
Evaluating Safety and Efficacy
Key focus will also be placed on safety, where the frequency and nature of serious adverse events will be closely monitored across both treatment groups. This structured approach ensures that researchers can collect valuable data regarding both the benefits and potential risks associated with SCI-110.
About SciSparc Ltd.
SciSparc Ltd. is not just focused on Tourette Syndrome; its vision encompasses a broader range of therapies aimed at rare central nervous system disorders. The company is engaged in the development of several promising drug programs. These include SCI-110 for Tourette Syndrome, aimed at not only improving the lives of those affected by TS but also exploring applications for Alzheimer’s disease and agitation.
Innovative Drug Development Programs
Additionally, SciSparc is working on SCI-210, which is intended for treating Autism Spectrum Disorder (ASD) and status epilepticus. The commitment to cannabinoid pharmaceutical technologies positions SciSparc as a leader in innovative treatments.
Connecting with Investors
The future looks promising for SciSparc as it continues to build an impressive portfolio of technologies. The company also has a controlling interest in a subsidiary focused on marketing hemp seed oil-based products through platforms like Amazon Marketplace. This diverse approach not only strengthens the company's market presence but also aligns with its objectives of enhancing available therapies for various medical conditions.
Frequently Asked Questions
What is the purpose of SciSparc's Phase IIb trial?
The Phase IIb trial aims to evaluate the efficacy, safety, and tolerability of the SCI-110 drug candidate in adults with Tourette Syndrome.
Where will the clinical trial take place?
The trial will be conducted at three prestigious centers: the Yale Child Study Center, Hannover Medical School, and Tel Aviv Sourasky Medical Center.
What are the primary measures for the trial?
The primary measures include changes in tic severity assessed by the Yale Global Tic Severity Scale and monitoring of adverse events.
What other conditions is SciSparc developing treatments for?
Besides Tourette Syndrome, SciSparc is also focused on developing therapies for Alzheimer’s disease, agitation, Autism Spectrum Disorder, and status epilepticus.
How can individuals contact the company for more information?
For inquiries, individuals can reach SciSparc at IR@scisparc.com or by calling +972 3-761-7108.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Spectral Capital's $15 Million Fundraising for Quantum Innovations
- WeRide and Uber Form Strategic Alliance for Robotaxi Rides
- Agricultural Organizations Call for Urgent Action on Ports Strike
- Brijjit Scar Therapy: Revolutionizing Scar Prevention for Patients
- Alumis Inc.'s ESK-001 Shows Promise for Psoriasis Treatment
- Analysts Predict Potential Surprises in Earnings for Key Stocks
- LEO Pharma Shows Positive Tralokinumab Results for AD Relief
- Middlefield Canadian Income PCC: Insights on NAV Performance
- Raise Achieves Bronze Accreditation for Indigenous Relations
- Altamira Therapeutics Expands Quality System Certification for Bentrio
Recent Articles
- Car-Mart Plans $65 Million Stock Offering for Growth and Expansion
- XLR8 America Teams Up with EVoke Systems for Enhanced EV Charging
- Exicure, Inc. Secures Extension for Nasdaq Listing Compliance
- Emera Increases Dividend for 18th Year - A Commitment to Shareholders
- Fifth Third Bank Sets New Prime Lending Rate for Customers
- Chegg Board Restructuring: New Directions for the Future
- RGP Plans to Release Q1 Fiscal 2025 Results Soon
- Robinhood Markets Stock Rises: Key Drivers Behind the Move
- Curbio CEO Rick Rudman Honored with HousingWire Vanguards Award
- Federal Government's Housing Announcement in Newfoundland
- Novo Nordisk and NanoVation Unveil $600M Genetic Medicine Deal
- Concentric AB Enhances Engineering Division with Strategic Purchase
- Investors of WEBTOON Entertainment: Join the Class Action!
- Investigating Potential Claims for Elastic N.V. Investors
- ACTFL Appoints Lawrence Paska as New Executive Director
- Investigating Adobe Inc.: Opportunities for Investors Unveiled
- Scholastic Corporation Declares New Quarterly Dividend Payment
- Revolutionary Glass Primer by Boston Industrial Solutions
- American Healthcare REIT Moves Forward with Stock Offering Plan
- Packsize Welcomes Brian Reinhart as Chief Revenue Officer
- Nuvalent Completes Successful Offering of Class A Common Stock
- Unselfish Love Takes Center Stage in New Documentary
- Bright Green Corporation Faces Market Turbulence with BGXX
- Trinity Biotech: Stock Decline & Positive Future Prospects
- Markforged Stock Declines to Record Low Amid Financial Struggles
- Gulf Central Banks Optimize Rates Amid Fed's Monetary Policy Shift
- Impact of Fed Rate Cuts on Credit Market Dynamics
- Vow ASA Announces Insider Trading Activity by CEO
- Empowering Veterans Through Face the Fight® Initiatives
- EA Reimagines The Sims Franchise with New Strategies Ahead
- Exploring the Growth of Reciprocal Insurance Entities
- Understanding the Impact of Fed's Recent Interest Rate Move
- Roku's Ambitious Move to Capitalize on Streaming Ad Trends
- Organon Takes Major Step Acquiring Dermavant for $1.2B
- Transforming Ordinary Investments into Extraordinary Wealth
- BeiGene's Cancer Drug Brukinsa: An Emerging Market Leader
- Teamsters Union Declines Endorsement for Presidential Candidates
- Curbio CEO Rick Rudman Celebrated with HousingWire Award
- Empowering Latino Health: National Kidney Foundation's Initiative
- BMO Financial Group Reduces Prime Rate Targeting Growth
- Trinity Capital Inc. Announces New Cash Dividend for Investors
- Exploring the Impact of Citizen Printer: A Monograph Journey
- LAZ Parking Celebrates Three Employees Recognized Among Stars
- DGSE Companies Inc (ELA) Reaches New Heights in Stock Value
- Putnam Premier Income Trust Achieves Record Stock High of $3.74
- SLXN Stock Hits Record Low as Investors Seek Stability
- Rari Capital Reaches Settlement with SEC Over Investor Misleading
- Legal Action Against Jetstar for Misleading Passenger Rights
- George Milligan's Share Purchase Signals Confidence in UFG
- Harvey Weinstein's Legal Battles Continue Amid New Charges